Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.

Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L; CESAME Study Group.

Aliment Pharmacol Ther. 2017 Feb;45(4):533-541. doi: 10.1111/apt.13897. Epub 2016 Dec 19.

PMID:
27995656
2.

Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, Cosnes J, Simon T, Peyrin-Biroulet L, Beaugerie L; CESAME study group.

Aliment Pharmacol Ther. 2016 Jan;43(2):252-61. doi: 10.1111/apt.13466. Epub 2015 Nov 9.

3.

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group.

Gut. 2014 Sep;63(9):1416-23. doi: 10.1136/gutjnl-2013-305763. Epub 2013 Oct 25.

PMID:
24162591
4.

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N; CESAME Study Group.

Inflamm Bowel Dis. 2012 Nov;18(11):2063-71. doi: 10.1002/ibd.22889. Epub 2012 Jan 23.

PMID:
22271569
5.

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group.

Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25.

PMID:
21708105
6.

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F; CESAME Study Group.

Lancet. 2009 Nov 7;374(9701):1617-25. doi: 10.1016/S0140-6736(09)61302-7.

PMID:
19837455
7.

[A case of hepatic sarcoidosis. Review of the literature].

Nores JM, Chesneau MC, Charlier JP, de Saint-Louvent P, Nenna AD.

Ann Gastroenterol Hepatol (Paris). 1987 Oct;23(5):257-60. Review. French.

PMID:
3314660
8.

Diffuse follicular lymphoid hyperplasia of the small intestine without primary immunoglobulin deficiency.

Rambaud JC, De Saint-Louvent P, Marti R, Galian A, Mason DY, Wassef M, Licht H, Valleur P, Bernier JJ.

Am J Med. 1982 Jul;73(1):125-32.

PMID:
7091167
9.

[Cytology of pancreatic juice collected during endoscopic retrograde cholangiopancreatography (author's transl)].

Bitoun A, de Saint-Louvent P, Bognel C, Bognel JC, Bernier JJ.

Gastroenterol Clin Biol. 1979 Nov;3(11):795-802. French. No abstract available.

PMID:
527790
10.

Iproclozide fulminant hepatitis. Possible role of enzyme induction.

Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP.

Gastroenterology. 1978 Sep;75(3):492-6.

PMID:
680506

Supplemental Content

Loading ...
Support Center